vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and Sunshine Biopharma Inc. (SBFM). Click either name above to swap in a different company.
Broadway Financial Corp is the larger business by last-quarter revenue ($9.4M vs $8.6M, roughly 1.1× Sunshine Biopharma Inc.). Broadway Financial Corp runs the higher net margin — 1934.0% vs -25.0%, a 1958.9% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -10.6%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-1.6M). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs 6.6%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Sunshine Biopharma Inc. is a clinical-stage biopharmaceutical company focused on researching, developing and commercializing innovative therapies for oncology, neurodegenerative disorders and infectious diseases. It targets unmet medical needs across global markets, with a pipeline of targeted therapeutic candidates designed to improve patient treatment outcomes.
BYFC vs SBFM — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $8.6M |
| Net Profit | $1.0M | $-2.1M |
| Gross Margin | — | 35.3% |
| Operating Margin | — | -20.9% |
| Net Margin | 1934.0% | -25.0% |
| Revenue YoY | 10.1% | -10.6% |
| Net Profit YoY | -21.8% | 0.8% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $8.6M | ||
| Q3 25 | $9.0M | $9.4M | ||
| Q2 25 | $8.1M | $9.4M | ||
| Q1 25 | $8.3M | $8.9M | ||
| Q4 24 | $8.6M | $9.6M | ||
| Q3 24 | $8.7M | $8.4M | ||
| Q2 24 | $8.2M | $9.3M | ||
| Q1 24 | $7.8M | $7.5M |
| Q4 25 | $1.0M | $-2.1M | ||
| Q3 25 | $-23.9M | $-883.8K | ||
| Q2 25 | $752.0K | $-1.8M | ||
| Q1 25 | $-2.7M | $-1.2M | ||
| Q4 24 | $1.3M | $-2.2M | ||
| Q3 24 | $516.0K | $-1.2M | ||
| Q2 24 | $256.0K | $-494.3K | ||
| Q1 24 | $-154.0K | $-1.3M |
| Q4 25 | — | 35.3% | ||
| Q3 25 | — | 32.6% | ||
| Q2 25 | — | 36.4% | ||
| Q1 25 | — | 30.7% | ||
| Q4 24 | — | 32.2% | ||
| Q3 24 | — | 34.0% | ||
| Q2 24 | — | 25.3% | ||
| Q1 24 | — | 31.2% |
| Q4 25 | — | -20.9% | ||
| Q3 25 | -256.2% | -11.5% | ||
| Q2 25 | 12.8% | -21.8% | ||
| Q1 25 | -45.3% | -14.6% | ||
| Q4 24 | 21.7% | -21.7% | ||
| Q3 24 | 8.5% | -13.1% | ||
| Q2 24 | 4.8% | -13.6% | ||
| Q1 24 | -2.9% | -17.9% |
| Q4 25 | 1934.0% | -25.0% | ||
| Q3 25 | -264.2% | -9.4% | ||
| Q2 25 | 9.3% | -18.8% | ||
| Q1 25 | -32.3% | -13.3% | ||
| Q4 24 | 15.3% | -22.5% | ||
| Q3 24 | 5.9% | -14.2% | ||
| Q2 24 | 3.1% | -5.3% | ||
| Q1 24 | -2.0% | -17.0% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-2.86 | $-0.54 | ||
| Q2 25 | $0.00 | $-0.82 | ||
| Q1 25 | $-0.39 | $-0.44 | ||
| Q4 24 | $0.07 | $49.77 | ||
| Q3 24 | $-0.03 | $-11.61 | ||
| Q2 24 | $0.02 | $-43.48 | ||
| Q1 24 | $-0.02 | $-2.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $23.0M |
| Total Assets | $1.3B | $30.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | — | ||
| Q3 25 | $19.7M | — | ||
| Q2 25 | $29.5M | — | ||
| Q1 25 | $15.8M | — | ||
| Q4 24 | $61.4M | — | ||
| Q3 24 | $97.1M | — | ||
| Q2 24 | $89.8M | — | ||
| Q1 24 | $67.1M | — |
| Q4 25 | $262.8M | $23.0M | ||
| Q3 25 | $261.7M | $24.2M | ||
| Q2 25 | $284.7M | $25.7M | ||
| Q1 25 | $283.6M | $22.7M | ||
| Q4 24 | $285.0M | $23.5M | ||
| Q3 24 | $286.2M | $25.0M | ||
| Q2 24 | $282.1M | $23.5M | ||
| Q1 24 | $281.1M | $24.8M |
| Q4 25 | $1.3B | $30.1M | ||
| Q3 25 | $1.3B | $31.5M | ||
| Q2 25 | $1.2B | $32.0M | ||
| Q1 25 | $1.3B | $29.2M | ||
| Q4 24 | $1.3B | $30.6M | ||
| Q3 24 | $1.4B | $30.1M | ||
| Q2 24 | $1.4B | $29.3M | ||
| Q1 24 | $1.4B | $31.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-1.6M |
| Free Cash FlowOCF − Capex | $-13.0K | $-1.6M |
| FCF MarginFCF / Revenue | -0.1% | -18.9% |
| Capex IntensityCapex / Revenue | 2.6% | 0.0% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-5.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-1.6M | ||
| Q3 25 | $3.8M | $-727.8K | ||
| Q2 25 | $3.0M | $-1.3M | ||
| Q1 25 | $-4.3M | $-1.7M | ||
| Q4 24 | $1.4M | $-3.4M | ||
| Q3 24 | $6.1M | $-1.4M | ||
| Q2 24 | $9.8M | $-4.6M | ||
| Q1 24 | $-11.7M | $-3.2M |
| Q4 25 | $-13.0K | $-1.6M | ||
| Q3 25 | $3.7M | $-735.8K | ||
| Q2 25 | $3.0M | $-1.4M | ||
| Q1 25 | $-4.4M | $-1.7M | ||
| Q4 24 | $1.3M | $-3.5M | ||
| Q3 24 | $6.1M | $-1.9M | ||
| Q2 24 | $9.7M | $-5.6M | ||
| Q1 24 | $-11.7M | $-3.2M |
| Q4 25 | -0.1% | -18.9% | ||
| Q3 25 | 41.1% | -7.8% | ||
| Q2 25 | 37.0% | -15.2% | ||
| Q1 25 | -52.4% | -19.3% | ||
| Q4 24 | 14.7% | -36.6% | ||
| Q3 24 | 69.6% | -22.2% | ||
| Q2 24 | 118.9% | -59.7% | ||
| Q1 24 | -149.7% | -43.1% |
| Q4 25 | 2.6% | 0.0% | ||
| Q3 25 | 1.2% | 0.1% | ||
| Q2 25 | 0.2% | 1.7% | ||
| Q1 25 | 0.2% | 0.1% | ||
| Q4 24 | 1.6% | 1.1% | ||
| Q3 24 | 0.3% | 6.1% | ||
| Q2 24 | 0.5% | 10.5% | ||
| Q1 24 | 0.7% | 0.8% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
